Zhejiang AngLiKang Pharmaceutical CO.,LTD.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Zhejiang Onlikang Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise that integrates pharmaceutical raw materials and pharmaceutical preparations, and features oral cephalosporins, cardiovascular drugs, and nephrotic drugs. The company has six holding subsidiaries: Zhejiang Onlikang Capsules Co., Ltd., Zhejiang Onlitai Pharmaceutical Co., Ltd., Jiangsu Yuexin Pharmaceutical Co., Ltd., Zhejiang Onbo Bioengineering Co., Ltd., Zhejiang Kangyun Huapeng Pharmaceutical Co., Ltd., and Zhejiang Onlikang Pharmaceutical Sales Co., Ltd. The company adheres to quality as the cornerstone of enterprise development and has established a comprehensive quality management system, covering the entire process from product research and development, raw material procurement, production and quality control, warehousing, product issuance to sales tracking. In accordance with GMP regulations, the company has established internal control quality standards higher than national statutory standards to ensure product quality. The company adheres to R&D innovation as the driving force for enterprise development. As a national high-tech enterprise, relying on excellent R&D platforms such as Zhejiang Key Enterprise Research Institute, Provincial Enterprise Technology Center, Academician Expert Workstation, Foreign Expert Workstation, and Postdoctoral Workstation, the company continuously promotes independent research and development. Currently, it has successfully accumulated a large number of core technologies and has an excellent R&D team of various professional talents, This has laid a rich foundation for the company to achieve independent drug research and development, achieving a leap from imitation to innovation, and from imitation to innovation. The company focuses on industry cooperation and strives to create greater value for its upstream and downstream partners with a sincere belief. It not only collaborates with Meifu Run, Ningbo Sanyuan, Zhuhai AIA, etc. in product production, but also cooperates with Wanpeng Lange, Suzhou Jingyun, Hongbo Zhiyuan, etc. in new product layout for research and development. It also collaborates with overseas returnee research and development teams to explore the field of innovative drugs, and also collaborates with the top 500 German companies, such as Fesenius Cabi Domestic pharmaceutical company Guangyao Baiyunshan and other industry leaders have established joint ventures, moving from competition to cooperation with numerous domestic and foreign peers, and sharing cutting-edge pharmaceutical technology and market. The company takes social responsibility as its mission and actively participates in caring for vulnerable groups. Together with the Red Cross Society of Shengzhou City, it has initiated the establishment of the "Zhejiang Onlikang Leukemia Relief Fund", and some families in need have received assistance; And actively participate in targeted poverty alleviation, pairing with Miao Family Village in Luo Township, Longyou County for assistance; We have also made continuous efforts in various aspects such as corporate governance, safe operation, green development, and social affairs, committed to achieving harmony and win-win results, reflecting the responsibility and sentiment of the people of Onlikang. Looking towards the future, the company will continue to focus on the pharmaceutical industry, integrate internal and external resources, take the opportunity of going public, increase investment in technological transformation and research and development innovation, adhere to the values of "integrity, passion, professionalism, respect, and cooperation", and with the vision of "healthy development, top 100 in the industry", build the company into an innovative international pharmaceutical enterprise with strong comprehensive competitiveness in the industry. |
| Headquarter | Shaoxing |
| Establish Date | 12/30/2001 |
| Listed Code | 002940.SZ |
| Listed Date | 10/23/2018 |
| Chairman | Fang Nanping. |
| CEO | Zheng Guogang. |
| Website | www.alkpharm.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
